C84.73 Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes (ICD-10 Code: C84.73)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, intra-abdominal lymph nodes, is a rare type of non-Hodgkin lymphoma originating from T-cells or null cells. It is characterized by large, abnormal lymphoid cells and typically presents as a systemic disease, though intra-abdominal lymph node involvement is specified here. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, leading to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Abdominal pain, bloating, or discomfort (if intra-abdominal involvement).
• Fatigue, loss of appetite, and general malaise.
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI) to assess lymph node involvement, and biopsy of affected tissue. Histopathological examination confirms the presence of large, abnormal lymphoid cells, and immunohistochemistry or molecular testing may be used to rule out ALK positivity and other subtypes. Staging helps determine the extent of disease.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens used for other aggressive lymphomas. Targeted therapies or immunotherapy may be considered based on individual factors. Radiation therapy may be used for localized disease or symptom control. Treatment plans are tailored to the patient’s overall health and disease stage.

Prognosis and Follow-Up

Prognosis varies based on factors like age, disease stage, and response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended, as late relapses can occur.

Complications

• Disease progression or recurrence.
• Organ dysfunction due to lymph node enlargement or infiltration.
• Treatment-related side effects (e.g., infection, cytopenias).
• Secondary malignancies from chemotherapy or radiation.

Lifestyle & Prevention

• Maintain a healthy lifestyle to support immune function.
• Avoid known immunosuppressive factors when possible.
• Follow recommended cancer screening guidelines for early detection of related conditions.

When to Seek Professional Help

Seek medical attention for persistent symptoms like unexplained weight loss, fever, night sweats, or abdominal pain. Prompt evaluation is critical if lymph node swelling or masses are noted, especially with systemic symptoms.

Tips for Medical Coders

Code C84.73 is specific to ALK-negative anaplastic large cell lymphoma involving intra-abdominal lymph nodes. Documentation should clearly specify the site (intra-abdominal lymph nodes) and confirm ALK negativity to support accurate coding. Ensure alignment with clinical findings and avoid coding for unspecified sites when the location is documented.